Monica Schwartz

Monica Schwartz

Company: Abalone Bio

Job title: Director


Panel Discussion: The Future of Biologics to Develop Next Generation GPCR-Targeted Therapeutics 9:00 am

Biologics offer great potential in developing therapeutics targeting GPCRs due to their high affinity, selectivity, and long half-life. While many antibodies to GPCRs are in clinical trials and two antibodies have been FDA approved, further effort is needed to promote the rate of advancement of biologics targeting GPCRs. We will discuss the current challenges and…Read more

day: Day Two

Discovery of Functional Antibody Drugs for GPCRs 2:00 pm

Functional GPCR antibodies, such as agonist and modulator antibodies, tap the hidden therapeutic potential of the body’s biological activities Abalone Bio’s Functional Antibody Selection Technology (FAST) platform couples a massively parallel in vivo search with data-powered selection to discover these ultra-rare antibodies Using the FAST platform, we have identified a highly specific CB2 agonist antibody…Read more

day: Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.